Registry collecting data and tumor samples from people with anaplastic thyroid cancer
Collects clinical information and tumor samples from adults with a rare, aggressive thyroid cancer.
Plain-language title generated from the registry record
Registry title: Taiwanese Anaplastic Thyroid Cancer Registry
Key facts
- Where
- Kaohsiung City, Sindian City, Taichung, Tainan, Taipei, and Taoyuan, TaiwanSee the 9 sites
Where in Taiwan
- Kaohsiung Medical UniversityKaohsiung City, TaiwanNo longer taking part
- National Taiwan University Hospital ,NTUH Hsin-Chu BranchSindian City, TaiwanNo longer taking part
- China Medical University HospitalTaichung, TaiwanNo longer taking part
- National Cheng Kung University HospitalTainan, TaiwanNo longer taking part
- Koo Foundation Sun Yat-Sen Cancer CenterTaipei, TaiwanNo longer taking part
- National Taiwan University HospitalTaipei, TaiwanNo longer taking part
- Taipei Veterans General HospitalTaipei, TaiwanNo longer taking part
- Tri-Service General HospitalTaipei, TaiwanNo longer taking part
- Chang Gung Memorial Hospital, LinkouTaoyuan, TaiwanNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- National Health Research Institutes, Taiwan
- Trial code
- NCT07138261
- Record updated
- 22 August 2025
- Original description
Primary treatment strategies for ATC have included surgical resection combined with radiotherapy, chemotherapy, or concurrent chemoradiation therapy. Despite these aggressive approaches, disease recurrence or progression remains frequently observed. Recent advances in molecular diagnostics and targeted therapy development have expanded treatment options for ATC patients with actionable genetic alterations, such as BRAF mutations or NTRK fusions. Nevertheless, for patients lacking identifiable targetable mutations, therapeutic options remain limited and clinical outcomes are poor. To address this unmet clinical need, the investigators aim to analyze baseline characteristics, treatment outcomes, and biomarker profiles from a larger cohort of ATC patients, with the goal of identification of predictive biomarkers and potential therapeutic targets. Given the rarity of ATC, conducting comprehensive studies at a single institution is challenging. Therefore, the investigators propose to establish a multi-center registry to systematically collect clinical data and tumor specimens from ATC patients.Read full original descriptionShow less
Taiwanese Anaplastic Thyroid Cancer Registry
Primary treatment strategies for ATC have included surgical resection combined with radiotherapy, chemotherapy, or concurrent chemoradiation therapy. Despite these aggressive approaches, disease recurrence or progression remains frequently observed. Recent advances in molecular diagnostics and targeted therapy development have expanded treatment options for ATC patients with actionable genetic alterations, such as BRAF mutations or NTRK fusions. Nevertheless, for patients lacking identifiable targetable mutations, therapeutic options remain limited and clinical outcomes are poor. To address this unmet clinical need, the investigators aim to analyze baseline characteristics, treatment outcomes, and biomarker profiles from a larger cohort of ATC patients, with the goal of identification of predictive biomarkers and potential therapeutic targets. Given the rarity of ATC, conducting comprehensive studies at a single institution is challenging. Therefore, the investigators propose to establish a multi-center registry to systematically collect clinical data and tumor specimens from ATC patients.
Inclusion: Pathologically or cytologically confirmed ATC and diagnosed after 2015; Capable of understanding and complying with the protocol requirements and signed informed consent. The dead patient can be enrolled without signed informed consent and they were dead before 2025.6.30.
Exclusion: Inability and unwillingness to give informed consent except dead patient; Patients refuse for collection of clinical data and follow up.